Psychological Treatment Provides Pain Relief for Chronic Back Pain
66 percent of patients randomly assigned to pain reprocessing therapy were pain-free after treatment compared with 20 percent in placebo group
Musculoskeletal Pain
MPR Weekly Dose Podcast Episode 92
This week we have news on pediatric influenza vaccine guidance; Moderna submit data for their COVID-19 booster dose; There’s new FDA warnings for some JAK inhibitors; Trudhesa nasal spray is approved; And the FDA places a clinical hold on a gene therapy for phenylketonuria.
Low Dose Naltrexone Designated Orphan Drug for Complex Regional Pain Syndrome
Anecdotal reports suggest that naltrexone, an opioid antagonist, may alleviate symptoms associated with CRPS.
Vazalore Liquid-Filled Aspirin Capsules Now Available Over the Counter
Vazalore™, a liquid-filled aspirin capsule, has been made available by PLx Pharma. Vazalore was approved by the Food and Drug Administration in March 2021. It is indicated for patients with vascular disease and those with rheumatologic diseases who are candidates for aspirin therapy. The product is designed to improve the absorption of aspirin by targeting…
Duloxetine Cuts Opioid Use After Total Knee Arthroplasty
Duloxetine, given on the day of surgery and once daily for 14 days, reduces opioid use by about 30 percent
Peripheral Nerve Stimulation May Cut Pain After Orthopedic Surgery
Pain scores, opioid consumption reduced in first postoperative week with percutaneous peripheral nerve stimulation versus sham treatment
Prevalence of Chronic Pain 20.5% in United States
Most common pain locations were back and hip, knee, or foot; physical therapy and massage most often used for management
FDA Panel Votes on Tanezumab for Osteoarthritis Pain
Tanezumab is a humanized monoclonal antibody that selectively targets, binds to, and inhibits nerve growth factor.
Digital Health App Tracks Pain Progress With Neurostimulation Therapy
Patients will be able to share information collected in the app with health care providers to provide a comprehensive assessment of the SCS or DRG therapy.
Elezanumab Granted Orphan Drug, Fast Track Designations for Spinal Cord Injury
Elezanumab is a monoclonal antibody of the human IgG1 isotype that works by binding selectively to repulsive guidance molecule A.
